{
  "docId": "019de070-1b1e-715b-9181-3c5ed2b300ba",
  "docSlug": "b1852bb8f228b7adee18c4b9e730fd78",
  "documentTitle": "Calliditas Therapeutics | IPO Presentation Deck | 38 slides",
  "authorId": "calliditas-therapeutics",
  "authorName": "Calliditas Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 38,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 18,
  "notes": "The table shows percentage changes or values for various renal markers. The 16mg dose consistently shows stronger efficacy (higher percentage reductions in protein/albumin) compared to 8mg.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-1b1e-715b-9181-3c5ed2b300ba/35",
  "deckHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba",
  "deckJsonHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba.json",
  "deckAnchorHref": "/decks/019de070-1b1e-715b-9181-3c5ed2b300ba#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.64,
        "x": 0.18,
        "y": 0.705
      },
      "kind": "paragraph",
      "text": "We selected 16mg dose for evaluation in our pivotal Phase 3 clinical trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ec7fe2f-144e-47cb-9c4e-8a79f322c25e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.08,
        "x": 0.09,
        "y": 0.885
      },
      "kind": "source-note",
      "text": "NEFIGAN trial.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1a434ab-c945-4d90-abf2-bcc1e9639cca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.47,
        "w": 0.66,
        "x": 0.17,
        "y": 0.238
      },
      "kind": "table",
      "text": "Table comparing Placebo, Nefecon 16mg, and Nefecon 8mg across 6 clinical metrics at 9 months.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72e5dbde-1fa9-4046-b346-466e2b4fd009",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.78,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Consistent trends support selection of 16 mg versus 8 mg",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f091ea0-e0ea-4189-81e2-aa6568d0a0c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "df791d77-6dba-45b1-94d0-2ded99575a12",
      "evidence": "Table comparing Placebo, Nefecon 16mg, and Nefecon 8mg across 6 clinical metrics at 9 months",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}